GlobeNewswire Inc | Aug 3, 2021 04:05PM EDT

August 03, 2021

EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zogenix(NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced thatStephenJ. Farr, Ph.D., President and Chief Executive Officer, andMichael Smith, Chief Financial Officer, will participate in a virtual fireside chat onTuesday, August 10, 2021, at theBofA SMID Cap 2H21 Ideas Conference.

Zogenix Fireside Chat DetailsDate: Tuesday, August 10, 2021 Time: 10:30 AM Eastern Time

The fireside chat will be webcast live and archived for 90 days onZogenix'sInvestor Relations website at https://zogenixinc.gcs-web.com.

About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

CONTACTS:

ZogenixMelinda BakerSenior Director, Corporate Communications+1 (510) 788-8732 |corpcomms@zogenix.com

InvestorsBrian RitchieManaging Director,LifeSci Advisors LLC+1 (212) 915-2578 |britchie@lifesciadvisors.com

MediaTrish McCallPorter Novelli+1 (805) 390-3279trish.mcall@porternovelli.com